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Background: Limited clinical data on real-world practice patterns are available for patients with metastatic/relapsed
soft tissue sarcomas (STS). The primary objective of this study was to evaluate treatment patterns in patients with
metastatic/relapsed STS following failure of prior chemotherapy by examining data collected from 2000 to 2011
from a major tertiary academic cancer center in the United States.
Methods: Medical records, including community-based referral records, from a tertiary cancer center for adult patients
with metastatic/relapsed STS with confirmed disease progression who commenced second-line treatment
between January 1, 2000 and February 4, 2011, and with at least 3 months of follow-up data following second-line
treatment initiation, were retrospectively reviewed. Overall survival, time to progression, and clinician-reported tumor
response were collected.
Results: A total of 99 patients (leiomyosarcoma, n = 48; synovial cell sarcoma, n = 7; liposarcoma, n = 5; or other
histological subtypes, n = 39) received an average of four lines of treatment (maximum of 10). No consistent or
dominant regimens were used in each treatment line beyond the second line. Median second-line treatment
duration was 4.1 months (95% confidence interval, 3.0–5.0). Overall, 72 of 99 patients (73%) discontinued second-line
treatment due to progressive disease. Median progression-free survival from initiation of second-line treatment varied
across regimens from 2.0 to 6.6 months (overall median, 5.4 months).
Conclusions: Wide variations in treatment were evident, with no single standard of care for patients with metastatic/
relapsed STS. Most patients discontinued second-line treatment due to progressive disease, often receiving additional
systemic therapy with other drugs. These data suggest a high unmet need for more efficacious treatment options and
improved data collection to guide practice among patients with relapsed/refractory STS.
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Soft tissue sarcomas (STS) are rare cancers of mesenchy-
mal cell origin that include more than 50 histological
subtypes, as well as many more molecularly distinct
entities [1,2]. STS can resemble the differentiation of
various connective tissues, including muscle fat, nerves,
vessels, stromal tissues, or bone. Gastrointestinal stromal
tumor (GIST) is the most common subtype of all sarco-
mas [3]. Other STS categories include leiomyosarcomas,
liposarcomas, and pleomorphic undifferentiated sarcoma
(formerly malignant fibrous histiocytoma) [3,4]. The
American Cancer Society estimated that 11 280 new
cases of STS were diagnosed and 3900 patients died in
2012 in the United States [4]. Survival estimates for
primary localized STS depend on many factors, including
anatomic location and tumor grade [1]. Despite treat-
ment, approximately 50% of patients with STS will ultim-
ately develop recurrences or metastatic disease [5,6].
For patients with primary resectable STS, surgery is
the mainstay of treatment [7,8]. However, for patients
with metastatic STS, systemic therapy with conventional
cytotoxic chemotherapy remains the main treatment
modality. The National Comprehensive Cancer Network
[7] and the European Society for Medical Oncology [8]
recommend anthracyclines (alone or combined with
other agents) in most cases as first-line treatment for
metastatic STS, although first-line treatment recommen-
dations may vary by histological subtype and previous
treatment. Until recently, doxorubicin was the only agent
formally approved by regulatory authorities for most
types of metastatic/relapsed STS [9]. Pazopanib, a multi-
targeted tyrosine kinase inhibitor, is now also approved
for use in patients following disease progression despite
prior chemotherapy based on clinical studies document-
ing the benefit of disease control in this population
[10,11]. Several other systemic agents, including ifosfa-
mide, gemcitabine, dacarbazine, and trabectedin, are
commonly used to treat metastatic/relapsed STS, but
evidence supporting these therapies is largely limited to
phase II trials [12-15].
Considering the wide range of STS histological sub-
types, it is difficult to draw conclusions for specific
entities based on generally uncontrolled trials of hetero-
geneous unselected patients with STS with a variety of
different treatments. In addition, information in the
published literature about treatment patterns and out-
comes in STS is sparse. Studies in the United States [16]
and internationally [6] showed a wide variety of systemic
therapy administered in patients following failure of
first-line chemotherapy.
Currently, there is no globally accepted standard based
on high-quality evidence for patients with advanced STS
following failure of prior chemotherapy to control ad-
vanced disease. The primary objective of this study wasto evaluate treatment patterns in patients with meta-
static/relapsed STS following failure of prior chemother-
apy by examining data collected from 2000 to 2011 from
a large tertiary academic cancer center in the United
States. For the purpose of this study, STS will refer to
sarcomas other than GIST. As a secondary objective,
this study sought to gain a high-level assessment of the
clinical effectiveness of various treatments given to pa-
tients with metastatic/relapsed STS.
Methods
This study was a retrospective analysis of patient medical
records from the Dana-Farber Cancer Institute affiliated
with Harvard Medical School in Boston, Massachusetts,
USA, and was approved by the Dana-Farber Cancer
Institute ethics committee.
All patients provided informed consent to approve the
use of their medical records based on an institutional re-
view board-approved protocol. Individual patient records
were retrospectively reviewed in a sequential manner
from this prospectively collected Sarcoma Center con-
sented registry, based upon a diagnosis of metastatic/
relapsed STS in patients aged 18 years or older who had
received at least two lines of systemic therapies with
initiation of second-line systemic therapy between
January 1, 2000 and February 4, 2011. In addition, docu-
mentation of confirmed disease progression on or after
first-line therapy and at least 3 months of data following
commencement of a second-line therapy were also
required.
Initially, data collection focused on patients with leio-
myosarcoma; however, enrollment was subsequently ex-
panded to include a broad range of STS histological
subtypes. Patients were excluded if they had been diag-
nosed with GIST, bone sarcoma, or dermatofibrosar-
coma protuberans, or had received treatment with
pazopanib (including experimental use). Patient data
were abstracted into an electronic case report form that
was independently reviewed and queried. Unless other-
wise specified, analyses presented here include all eli-
gible patients and histological subtypes.
For the analysis, the variables collected from the med-
ical records included patient demographics, histological
subtype, treatment type and duration for all lines of
systemic therapy, adverse events leading to treatment
modifications (e.g. discontinuation), overall survival,
clinician-reported tumor response rate, and progression-
free survival (PFS; calculated as time to clinician-
reported tumor progression or date of death, whichever
came first). Clinician-reported responses were based on
imaging results, if available, and/or clinical assessment
notes by the treating physician. The treating oncologist’s
written evaluation in the medical record was used to de-
fine a tumor response, rather than strictly limited to the
Table 1 Patient demographics and clinical characteristics
Patients evaluated N = 99
Female, % 62
Median age, years 51.9
Patients alive at time of data abstraction, % 37
History of surgery, % 87
Histological subtype, %
Leiomyosarcoma 48
Synovial cell sarcoma 7
Liposarcoma 5
Other: 39
Alveolar soft part sarcoma 5
Clear cell sarcoma 4
Dedifferentiated liposarcoma 4
Solitary fibrous tumor 4





Epithelioid and round cell malignant neoplasm, desmoplastic
small round-cell sarcoma, epithelioid sarcoma, epithelioid
hemangioendothelioma, myxoid liposarcoma, rhabdomyosarcoma,
round cell sarcoma, spindle cell sarcoma, undifferentiated sarcoma,
and uterine sarcoma
1 Each
Reason for discontinuing second-line therapy, %
Progressive disease 73




Developed second primary malignancya 1
Patient request 1
Avoidance of cumulative toxicity 1
Unclear 6
aOne patient developed a new primary colon carcinoma.
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ation Criteria in Solid Tumors (RECIST) to define “object-
ive responses.”
For the purpose of data analysis, patients were catego-
rized according to the following types of second-line
systemic therapy received: gemcitabine-based (including
gemcitabine plus docetaxel), anthracycline-based (includ-
ing anthracycline combined with other agents like ifosfa-
mide), alkylating agents (including ifosfamide monotherapy),
taxane-based, investigational agents (trabectedin, angio-
genesis inhibitors), or other.
Continuous variables were summarized as means with
standard deviation or median and range, as appropriate.
Categorical variables were summarized by absolute fre-
quencies and percentages. Time-to-event statistics were
computed using Kaplan-Meier survival analyses.
Results
Of the 99 patients with metastatic/relapsed STS included
in this analysis, the mean age was 51.9 years and 62%
were women (Table 1). Approximately one-half of the
patients (48%) had leiomyosarcoma, and about 67% of
the patients in this referral center population had partic-
ipated in a clinical trial at some point in their care.
The primary reason for treatment discontinuation
of second-line therapy was progressive disease, which
accounted for 73% of patients (Table 1). Only 10% were
considered to have “completed” their course of therapy prior
to developing progressive disease or discontinuing due to
adverse events. Six percent of patients discontinued second-
line therapy due to an adverse event.
One selection criterion for this study was that all pa-
tients were required to have had first- and second-line
systemic therapies. This study population then received
subsequent systemic therapy as follows: 78.8% had third-
line, 49.5% had fourth-line, and 35.5% received fifth-line
therapies. The maximum number of lines of systemic
therapies received was 10. Figure 1A summarizes these
treatments.
For patients receiving first-line treatment, 44% re-
ceived anthracycline-based therapy, and a significant
fraction (28%) received gemcitabine-based regimens as
first-line therapy (Figure 1A). For patients with leiomyo-
sarcoma, no clear difference was seen in the initial treat-
ment regimens received by patients with uterine
leiomyosarcoma versus non-uterine leiomyosarcoma
(Table 2).
For patients receiving second-line systemic therapy,
gemcitabine-based therapies were commonly used
(28%), with a similar percentage of patients receiving
anthracycline-based therapies (24%) (Figure 1A).
Second- and third-line treatment patterns according to
histological subtype did not suggest any clear trends
(Figure 1B).Median PFS from initiation of second-line treatment
varied somewhat across regimens, ranging from 2.0 to
6.6 months (overall median [95% confidence interval
(CI)], 5.4 months [3.3–7.0]). Median PFS (95% CI) was
6.4 months (3.0–16.5) for gemcitabine-based therapy
(n = 28), 5.8 months (2.3–8.0) for anthracycline-based
therapy (n = 24), 3.7 months (1.4–13.6) for trabectedin
(n = 13), 2.0 months (0.7–5.1) for alkylating agents (n =
12), 6.5 months (1.0–8.4) for angiogenesis inhibitors (n =
7), 4.7 months (2.0–7.0) for taxane-based agents (n = 3),
and 6.6 months (2.4–18.1) for other agents (n = 7).
Median duration for second-line treatment across all
regimens was 4.1 months (95% CI, 3.0–5.0). A clinician-
AB
Figure 1 Systemic therapy treatment patterns. Treatment patterns according to (A) therapy line, and (B) second-line and third-line systemic
therapy received according to histological subtype. *Patients were required to have at least one second-line systemic therapy for soft tissue sarcomas
to be eligible for this study. Therefore, the first-line therapy distribution was based on those patients receiving at least one additional line of
therapy (i.e. second-line or second-line plus additional lines of therapy).
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patients during any individual line of systemic therapy
(Table 3). Just over one-third of patients (n = 38/99
[38%]) had a clinician-documented response to any line
of chemotherapy. The mean duration of any line of ther-
apy beyond first-line treatment was in the range of 2 to
6 months (Table 3), documenting the frequent incidence
of treatment discontinuation or switching, possibly dueTable 2 Comparison of first-line treatments for uterine
versus non-uterine LMS
Treatment Uterine LMS Non-uterine LMS Total LMS
(n = 24), (n = 24), (N = 48),
n (%) n (%) n (%)
Anthracycline-based 7 (29.2) 11 (45.8) 18 (37.5)
Gemcitabine-based 11 (45.8) 10 (41.7) 21 (43.8)
Alkylating agents 1 (4.2) 1 (4.2) 2 (4.2)
Angiogenesis inhibitors 1 (4.2) 1 (4.2) 2 (4.2)
Trabectedin 2 (8.3) 1 (4.2) 3 (6.3)
Other 2 (8.3) 0 (0.0) 2 (4.2)
Abbreviation: LMS leiomyosarcomas.to lack of efficacy, toxicity, patient intolerance, or other
adverse factors.
The median overall survival from initial STS diagnosis
was 4.8 years (95% CI, 3.6–5.6) in this highly selected
referral center population of patients with metastatic/
relapsed STS (Figure 2). The median overall survival
from first diagnosis of metastatic STS was 3.3 years (95%
CI, 2.4–4.5).
Discussion
The goals of this retrospective study were to assess
treatment patterns for metastatic/relapsed STS and to
identify whether any consistent “standard of care” for
metastatic/relapsed STS could be identified in clinical
practice from this population of patients generally
treated in the community prior to referral to a tertiary
care academic medical center in the United States. The
only general trend identified was in the choice of initial
treatment regimen. Most patients received anthracycline-
based and gemcitabine-based therapy for first-line and
second-line treatment, respectively. Notably, a high per-
centage of patients received gemcitabine-based therapy as
first-line treatment of STS, and these patients generally









Time from initiation of previous therapy
to current therapy, months, mean (SD)
First-line 99 19 (18.8) 6.0 (7.4) N/A
Second-line 99 15 (15.2) 5.4 (5.3) 12.3 (13.4)
Third-line 78 8 (11.1) 4.1 (4.2) 9.9 (12.1)
Fourth-line 49 5 (11.4) 5.3 (9.1) 6.2 (5.6)
Fifth-line 35 4 (12.5) 4.2 (5.2) 5.0 (3.6)
Sixth-line 20 2 (11.1) 3.2 (3.7) 7.3 (7.4)
Seventh-line 15 1 (7.7) 1.7 (1.1) 5.7 (6.0)
Eighth-line 7 1 (16.7) 4.1 (3.3) 5.7 (6.5)
Ninth-line 6 0 (0.0) 2.2 (2.2) 7.9 (9.6)
Tenth-line 2 0 (0.0) 3.9 (5.0) 4.4 (1.6)
Most recent therapy 99 13 (12.9) 3.6 (6.3) 8.7 (9.6)
Abbreviations: N/A not available; SD standard deviation.
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first-line regimen. However, no clear patterns for third-
line therapy and beyond were noted. In addition, there
was no clear link between histological subtypes and any
particular treatment patterns.
A retrospective study describing international treat-
ment patterns, the Sarcoma Treatment and Burden of
Illness in North America and Europe (SABINE) study,
similarly found that anthracycline-based regimens were
most commonly used as first-line therapy in metastatic/
relapsed STS [6]. The most common STS subtype in the
SABINE study was leiomyosarcoma (46.5%). Doxorubi-
cin monotherapy (34%) or an anthracycline (doxorubicin
or epirubicin) combined with ifosfamide (30%) were
identified as the most common first-line treatments in
the SABINE study, which contrasts to more diverse first-
line options in this study with 44% of patients receiving
anthracycline-based therapy. The most common second-
line treatment in the SABINE study was gemcitabine
plus docetaxel (18.0%). This is similar to the 28% of
patients who received gemcitabine-based therapy in theFigure 2 Overall survival from initial diagnosis of STS and from diagnospresent study—who predominantly received gemcitabine
plus docetaxel. The common use of gemcitabine in both
studies could be related to the high proportion of pa-
tients with leiomyosarcoma in this study sample. The
SABINE study found that trabectedin, which is approved
for use in Europe but is only available as an investiga-
tional agent in the United States at specific centers, was
commonly used after failure of first- and second-line
therapy, which is consistent with results here. Similar to
the observations noted in our study, the proportion of
favorable responses to chemotherapy in the SABINE
study declined with additional lines of treatment.
The majority of patients in the current study discon-
tinued second-line treatment due to progressive disease
and received additional lines of treatment. Less than
20% of these patients had a favorable response to treat-
ment during any line of therapy (Table 3).
The median overall survival from diagnosis of meta-
static disease was 3.3 years (39 months) in our study,
which was considerably longer than the 10 to 18 months
frequently reported in the literature for metastatic/is of metastatic/relapsed STS. Abbreviation: STS soft tissue sarcoma.
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ported a similar median overall survival from diagnosis of
metastatic disease of 33.3 months [6]. It was not possible to
assess the contribution of referral bias of more fit patients
to tertiary care sarcoma centers versus the value of highly
coordinated expert care delivered by sarcoma-dedicated
teams, but these components could have contributed to
longer survival. It is also likely that patients who go on to
receive at least two rounds of chemotherapy have a better
prognosis than those patients who might be too frail to
receive chemotherapy. The high proportion of patients
participating in clinical trials (67%) is also consistent with
the hypothesis that this referral center patient population is
likely to have fewer adverse clinical factors that could
negatively influence survival.
Although data suggest that survival has somewhat
improved in patients with sarcoma over the past two
decades, the overall outcomes of metastatic STS remain
poor. Italiano and colleagues [18] reported that overall
survival of patients with metastatic/relapsed STS in
the French Sarcoma Group database improved from
14 months (1987–1991) to 18 months (2002–2006).
Multimodal treatment approaches may account for some
improvement in survival over time [19,20]. Despite these
improvements, a pressing need remains for more effect-
ive treatment options of these life-threatening diseases.
Effectiveness results from this study may not be fully
representative of the broader metastatic/relapsed STS
population given the selected patient population treated
in a single tertiary sarcoma center. This retrospective
analysis also used a practice-based approach to defining
criteria for response rates and disease progression com-
pared with the rigorously standardized criteria used in a
clinical trial setting (e.g. RECIST), which may also con-
found direct comparisons between the effectiveness data
from such a practice-based review and prospectively
defined clinical research trials. In addition, the small
number of patients included from a single tertiary care
center led to wide CIs, particularly in the subtypes, and
may limit the generalizability of these findings, although
the data reviewed included community-based practice
assessments of treatment regimens prior to referral to
the academic center.
STS represents a diverse and varied collection of histo-
logical subtypes with distinct biological characteristics,
natural histories, and responses to treatment. Because of
the heterogeneity of patients receiving later lines of ther-
apy, conclusions about these very limited subsets of the
STS population should be made with care. Considering
histological subtypes, the STS subtypes represented in
our study do not reflect the natural distribution, and
only leiomyosarcomas, which comprised 48% of our
sample, were adequately represented. Of note, 39% of
the population was derived from “other” subgroups, thusmaking assessment difficult and clouding the ability to
identify uniform standards.
Conclusions
This retrospective analysis from a large academic cancer
center shows wide variation in treatment patterns, includ-
ing switching between anthracycline- and gemcitabine-
based therapy in early lines and significant heterogeneity
in decisions regarding later lines of treatment. The major-
ity of patients discontinued second-line treatment due to
progressive disease and often received additional lines of
treatment, with frequent switching of treatment. A signifi-
cant unmet medical need exists for effective treatments
among patients with metastatic/relapsed STS.
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